



PATENT

RECEIVED

MAY 24 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ruth A. Chenault and Jiangchun Xu  
Application No. : 09/997,279  
Filed : November 28, 2001  
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND  
DIAGNOSIS OF OVARIAN AND ENDOMETRIAL CANCER  
Art Unit : 1631  
Docket No. : 210121.501C1

Commissioner for Patents  
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 C.F.R. § 1.98, are enclosed). Documents on the attached Form PTO-1449 were cited in an Invitation to Pay Additional Search Fees for corresponding foreign application PCT/US01/09062, mailed April 17, 2002, a copy of which is enclosed.


Applicants' note that reference AD (WO 99/54461) is written in German. Accordingly, the Examiner's attention is respectfully directed to the cover page which contains an English abstract.

Applicants' note that reference AE (WO 99/53040) is written in German. Accordingly, the Examiner's attention is respectfully directed to the cover page which contains an English abstract.

As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Julie A. Urvater, Ph.D.  
Registration No. 50,461

JEH:mls

Enclosures:

Postcard  
Form PTO/SB/21  
Form PTO-1449  
Copies of Cited References (8)  
Copy of Invitation to Pay Additional Fees for PCT/US01/09062

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.501C1APPLICATION NO.  
09/997,279SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

(Use several sheets if necessary)

APPLICANTS

Ruth A. Chenault and Jiangchun Xu

FILING DATE

November 28, 2001

GROUP ART UNIT

1631

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE APPROPRIATE
	AA	5,976,799	11/02/99	O'Brien et al.	435	6	
	AB						
	AC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AD	WO 99/54461	10/28/99	WIPO		X
	AE	WO 99/53040	10/21/99	WIPO		X
	AF					
	AG					
	AH					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	Cohen et al., "Human SLUG gene organization, expression and chromosome map location on 8q," <i>Genomics</i> 51(3):468-471, August 1, 1998.
	AJ	Database EMBL Accession Number AI699775, June 4, 1999.
	AK	Database EMBL Accession Number H61817, October 8, 1995.
	AL	Database EMBL Accession Number AF042001, February 5, 1998.
	AM	Inukai et al., "SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein," <i>Molecular Cell</i> 4(3):343-352, September 1999.
	AN	Sjogren et al., "Therapeutic immunization against cancer antigens using genetically engineered cells," <i>Immunotechnology</i> 3(3):161-172, October 1997.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Date: